respiratory
Cystic fibrosis

Access to cystic fibrosis drug widens


Children aged 2 to 5 living with cystic fibrosis will be able to access ivacaftor (Kalydeco) on the PBS, the federal government has announced. Prior to today’s announcement only children six years of age and older with the G551D or other class III gating mutations had subsidised access to the drug. Ivacaftor will be formally ...

Already a member?

Enter your email to keep reading.


OR